https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-02-07 / Curr. Opin. Immunol. 2006 Apr;18(2):201-5
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-02-07 / Curr. Opin. Immunol. 2006 Apr;18(2):201-52006-02-07 00:00:002019-02-15 09:24:17Therapeutic cancer vaccines
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-01-01 / Curr. Pharm. Des. 2006;12(7):807-17
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-01-01 / Curr. Pharm. Des. 2006;12(7):807-172006-01-01 00:00:002019-02-15 09:24:18Immunotherapy for prostate cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-11-10 / J. Clin. Oncol. 2005 Nov;23(32):8262-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-11-10 / J. Clin. Oncol. 2005 Nov;23(32):8262-92005-11-10 00:00:002019-02-15 09:24:19Prostate cancer immunology: biology, therapeutics, and challenges
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-11-01 / Int J Hyperthermia 2005 Nov;21(7):649-56
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-11-01 / Int J Hyperthermia 2005 Nov;21(7):649-562005-11-01 00:00:002019-02-15 10:00:37Hyperthermia combined with radiation in treatment of locally advanced prostate cancer is associated with a favourable toxicity profile
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-10-03 / Br. J. Cancer 2005 Oct;93(7):749-56
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-10-03 / Br. J. Cancer 2005 Oct;93(7):749-562005-10-03 00:00:002019-02-15 09:24:20Immunotherapy with allotumour mRNA-transfected dendritic cells in androgen-resistant prostate cancer patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-09-01 / Aktuelle Urol 2005 Sep;36(5):407-16
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-09-01 / Aktuelle Urol 2005 Sep;36(5):407-162005-09-01 00:00:002019-02-15 09:24:21[Vaccine therapy of prostate cancer]
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-01-01 / Nat Clin Pract Urol 2005 Jan;2(1):44-51
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-01-01 / Nat Clin Pract Urol 2005 Jan;2(1):44-512005-01-01 00:00:002019-02-15 09:24:18Technology Insight: vaccine therapy for prostate cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-01-01 / Strahlenther Onkol 2005 Jan;181(1):35-41
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-01-01 / Strahlenther Onkol 2005 Jan;181(1):35-412005-01-01 00:00:002019-02-15 10:00:38Regional hyperthermia in conjunction with definitive radiotherapy against recurrent or locally advanced prostate cancer T3 pN0 M0
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-12-01 / J. Urol. 2004 Dec;172(6 Pt 2):2532-8
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-12-01 / J. Urol. 2004 Dec;172(6 Pt 2):2532-82004-12-01 00:00:002019-02-15 09:24:22Dendritic cell based vaccines: progress in immunotherapy studies for prostate cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-01-01 / BJU Int. 2004 Jan;93(1):36-41
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-01-01 / BJU Int. 2004 Jan;93(1):36-412004-01-01 00:00:002019-02-15 10:00:39Radiotherapy and hyperthermia in the treatment of patients with locally advanced prostate cancer: preliminary results
